One Case of Adrenocortical Insufficiency Caused by Cadonilimab

doi:10.19803/j.1672-8629.20240554

Abstract

Abstract: Objective To analyze the clinical characteristics, risk factors, and treatment of adrenal insufficiency caused by cadonilimab and to explore the role of clinical pharmacists in the management of immune-related adverse events. Methods A case of 3rd grade adrenal insufficiency caused by cadonilimab was analyzed, and the related literature was summarized. Clinical pharmacists gave advice on management of adverse reactions, pharmaceutical care and medications. Results The fatigue, nausea, and hyponatremia experienced by the patient after receiving cadonilimab were likely attributed to immune-related adrenocortical insufficiency. After discontinuation of cadonilimab and start of oral steroid therapy, the patient had no more discomfort with good compliance. Conclusion During the treatment with cadonilimab, it is important to monitor the patient's clinical symptoms, such as fatigue, nausea, hyponatremia, which may indicate the chance of drug-related adrenal insufficiency. Quick countermeasures can be crucial to improving the patient's prognosis.

Key words: Cadonilimab, Immune Checkpoint Inhibitors (ICIs), Immune-Related Adverse Event, Adrenal Insufficiency, Hypophysitis, Clinical Pharmacists

CLC Number:

LIU Nannan, XI Yalin, CHEN Zhe. One Case of Adrenocortical Insufficiency Caused by Cadonilimab[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240554

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I1/109

References

[1] KEAM SJ.Cadonilimab: First Approval[J]. Drugs, 2022, 82(12): 1333-1339.
[2] XU Q, XU T.A Case of Pituitary Crisis Caused By Cadonilimab Treatment of Advanced Gastric Cancer[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2024, 33(1): 116-120.
[3] FAJE AT, SULLIVAN R, LAWRENCE D, et al.Ipilimumab-Induced Hypophysitis: a Detailed Longitudinal Analysis in a Large Cohort of Patients with Metastatic Melanoma[J]. J Clin Endocrinol Metab, 2014, 99(11): 4078-4085.
[4] ASCIERTO PA, DEL VECCHIO M, ROBERT C, et al.Ipilimumab 10 mg·kg^-1 vs Ipilimumab 3 mg·kg^-1 in Patients with Unresectable or Metastatic Melanoma: a Randomised, Double-Blind, Multicentre, Phase 3 Trial[J]. Lancet Oncol, 2017, 18(5): 611-622.
[5] CHANG LS, BARROSO-SOUSA R, TOLANEY SM, et al.Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65.
[6] Immune-Endocrinology Group, Chinese Society of Endocrinology, Chinese ledical Association. Chinese Expert Consensus on the Immune Checkpoint Inhibitors-Induced Endocrine Immune-Related Adverse Events(2020)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2021, 37(1): 1-16.
[7] WRIGHT JJ, POWERS AC, JOHNSON DB.Endocrine Toxicities of Immune Checkpoint Inhibitors[J]. Nat Rev Endocrinol, 2021, 17(7): 389-399.
[8] SALABEI JK, UPADHYAY D, PADAM SA.Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma[J]. HCA Healthc J Med, 2021, 2(5): 339-343.
[9] Obesity Group, Chinese Society of Endocrinology, Chinese Medical Association. Expert Consensus on the Management of Glucocorticoids During the Perioperative Period for Patients with Adrenal Insufficiency[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2022, 38(1): 1-6.
[10] MIHIC-PROBST D, REINEHR M, DETTWILER S, et al.The Role of Macrophages Type 2 and T-Regs in Immune Checkpoint Inhibitor Related Adverse Events[J]. Immunobiology, 2020, 225(5): 152009.
[11] CATUREGLI P, DI DALMAZI G, LOMBARDI M, et al.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade[J]. Am J Pathol, 2016, 186(12): 3225-3235.
[12] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Immune Checkpoint Inhibitor-Related Toxicity Management Guidelines[中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南][M]. Beijing: People's Medical Publishing House, 2023.
[13] SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, et al.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update[J]. J Clin Oncol, 2021, 39(36): 4073-4126.
[14] U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version5.0[EB/OL]. (2017-11-27) [ 2024-06-13]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
[15] Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Principles for Clinical Application of Glucocorticoids(2023 Edition)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2023, 39(4): 289-296.
[16] National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities(Version 1.2024) [EB/OL]. (2023-12-07) [2024-06-13]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1486.
[17] HAANEN J, OBEID M, SPAIN L, et al.Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up[J]. Ann Oncol, 2022, 33(12): 1217-1238.